Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. (Q50555797)

15 March 2018

title

Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. (English)

1 reference

15 March 2018

1 reference

Yuan-Hung Kuo

1

1 reference

15 March 2018

Tang-Wei Chuang

2

1 reference

15 March 2018

Chao-Hung Hung

3

1 reference

15 March 2018

Chien-Hung Chen

4

1 reference

15 March 2018

Jing-Houng Wang

5

1 reference

15 March 2018

Tsung-Hui Hu

6

1 reference

15 March 2018

Sheng-Nan Lu

7

1 reference

15 March 2018

Chuan-Mo Lee

8

1 reference

15 March 2018

publication date

1 June 2011

1 reference

15 March 2018

Journal of the Formosan Medical Association

published in

1 reference

15 March 2018

volume

110

1 reference

15 March 2018

issue

6

1 reference

15 March 2018

page(s)

363-371

1 reference

15 March 2018

Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

The spectrum of extrahepatic manifestations in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Association of diabetes mellitus and chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Association of hepatitis C virus in human sera with beta-lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Metabolic profiles in patients with chronic hepatitis C: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Cholesterol and lipoprotein levels as predictors of response to interferon for hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatitis C virus particles and lipoprotein metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Tumor necrosis factor-alpha, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2811%2960054-5

7 January 2021

10.1016/S0929-6646(11)60054-5

Identifiers

DOI

1 reference

15 March 2018

PubMed ID

21741004

1 reference

15 March 2018